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Introduction 
In Creutzfeldt-Jakob disease (CJD), molecular typing based on the size of the protease 
resistant core of the disease-associated prion protein (PrPSc) and the M/V polymorphism at 
codon 129 of the PRNP gene correlates with the clinico-pathologic subtypes. Approximately 
95% of the sporadic 129MM CJD patients are characterized by cerebral deposition of type 1 
PrPSc and correspond to the classic clinical CJD phenotype. The rare 129MM CJD patients 
with type 2 PrPSc (MM2) are further subdivided in a cortical and a thalamic form, also 
indicated as sporadic Fatal Insomnia (sFI). To define the diversity between the MM2 
subtypes, we characterized two different cases of MM2-thalamic CJD in terms of clinical, 
neuropathological, biochemical and transmission properties. 
 
Material and Methods 
Two young patients, both MM at codon 129 and affected by a thalamic form of CJD, were 
followed up to describe the clinical course and, after autopsy, the neuropathological and 
biochemical features were characterized. To evaluate the transmission properties, a group of 
gene targeted transgenic mice expressing human PrP on a mouse PrP knock-out background 
and carrying the MM 129 codon genotype (HuMM) were injected by a combination of 
intracerebral (i.c.) (20 μl) and intraperitoneal (i.p.) (100 μl) routes with 10% homogenate of 
cerebral cortex from one of the two MM2-thalamic cases. 
 
Results 
Main neuropathological features in the two cases were diffuse, synaptic PrP 
immunoreactivity in the cerebral cortex and severe neuronal loss and gliosis in the thalamus 
and olivary nucleus. Western blot analysis showed the presence of type 2A PrPSc. Challenge 
of transgenic mice expressing 129MM human PrP showed that MM2-thalamic sCJD 
transmitted the disease to 13 out of 14 mice, with an incubation time of 535 ± 32 (mean ± 
s.e.m) days and a survival period of 557 ± 23 (mean ± s.e.m) days. All affected mice showed 
mild spongiform changes in the brain and the presence of a type 2A PrPSc. Conversely, no 
clinical signs, neuropathological changes and PrPSc accumulation were observed in mice (n 
= 16) injected with a MM2-cortical case, up to 650 days post-inoculation. 
 
 Conclusions 
Our data indicate that the MM2-thalamic form of CJD shows peculiar clinical, 
neuropathological and biochemical characteristics, and is capable to transmit the disease 
to mice expressing the human 129MM PRNP, at variance with MM2-cortical sCJD. The 
affected mice showed deposition of type 2A PrPSc, a scenario that is unprecedented in this 
mouse line. These data indicate that MM2-thalamic sCJD is caused by a prion strain distinct 
from the other sCJD subtypes including the MM2-cortical form. 
 
